Durvalumab Consolidation Should Be the Standard Therapy in Stage III EGFR-Mutant NSCLC After Chemoradiation

被引：5
|
作者：
Morgensztern, Daniel [1 ]
Govindan, Ramaswamy [1 ]
机构：
[1] Washington Univ, Div Med Oncol, Dept Med, Sch Med, St Louis, MO 63110 USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2021年 / 16卷 / 12期
关键词：
CELL LUNG-CANCER; CHECKPOINT INHIBITORS; SURVIVAL;
D O I：
10.1016/j.jtho.2021.07.034
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：1999 / 2001
页数：3
相关论文
共 50 条
  • [31] ILLUMINATE: Efficacy and Safety of Durvalumab/ Tremelimumab and Chemotherapy in EGFR-Mutant NSCLC Following Progression on EGFR Inhibitors
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2023, 21 (10) : 8 - 9
  • [32] Consolidation therapy with Durvalumab after radical CRT in stage IIII NSCLC: a preliminar analysis
    Borghetti, P.
    Volpi, G.
    Imbrescia, J.
    Bonu, M. L.
    Guerini, A.
    Turla, O.
    Maddalo, M.
    Vitali, P.
    Triggiani, L.
    Donofrio, A.
    Buglione, M.
    Magrini, S. M.
    RADIOTHERAPY AND ONCOLOGY, 2020, 152 : S547 - S548
  • [33] Identification of predictive factors for early relapse in patients with unresectable stage. NSCLC receiving consolidation durvalumab after concurrent chemoradiation therapy
    Nam, Jung Hyun
    Yeo, Chang Dong
    Park, Chan Kwon
    Kim, Sung Kyoung
    Kim, Ju Sang
    Kim, Yong Hyun
    Kim, Jin Woo
    Kim, Seung Joon
    Lee, Sang Haak
    Kang, Hye Seon
    EUROPEAN RESPIRATORY JOURNAL, 2023, 62
  • [34] Bronchomediastinal Fistula During Durvalumab Therapy After Chemoradiotherapy in Stage III NSCLC
    Sumi, Toshiyuki
    Ikeda, Takumi
    Kure, Kenichi
    Yamada, Yuichi
    Nakata, Hisashi
    Mori, Yuji
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : 1860 - 1861
  • [35] EGFR Tyrosine Kinase Inhibitor Monotherapy Should Remain the Standard First-Line Treatment in Advanced EGFR-Mutant NSCLC
    Stock-Martineau, Sophie
    Shepherd, Frances A.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (11) : 1793 - 1797
  • [36] Durvalumab after Chemoradiotherapy is currently the most promising Therapy in Stage III NSCLC
    Wilhelm, Martin
    STRAHLENTHERAPIE UND ONKOLOGIE, 2019, 195 (07) : 691 - 692
  • [37] Almonertinib With Radiotherapy vs Concurrent Chemoradiotherapy in Unresectable Stage III EGFR-mutant NSCLC (ADVANCE Trial)
    Bi, N.
    Jiang, W.
    Chen, M.
    Fu, X. L.
    Wang, L.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S1104 - S1105
  • [38] Evaluating Risk Factors for Pneumonitis in Stage III NSCLC Patients Receiving Durvalumab after Definitive Chemoradiation
    Mo, X.
    Dong, L.
    Patel, S.
    DiCostanzo, D.
    Alahmadi, A.
    Kaufman, J.
    Memmott, R.
    He, K.
    Bertino, E.
    Presley, C.
    Shields, P.
    Otterson, G.
    Carbone, D. P.
    Welliver, M. X.
    Owen, D. H.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S389 - S389
  • [39] Incidence and Outcomes of Brain Metastases in Unresectable Stage III Patients with NSCLC Treated with Durvalumab after Chemoradiation
    Patel, S.
    Zhao, S.
    Wei, L.
    Li, M.
    Bertino, E.
    Presley, C.
    Welliver, M.
    Haglund, K.
    Palmer, J.
    Arnett, A.
    Beyer, S.
    Mende, E.
    Elder, J.
    Hardesty, D.
    Shields, P.
    Carbone, D.
    Otterson, G.
    Williams, T.
    Owen, D.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S363 - S364
  • [40] Optimization of treatment options for EGFR-mutant, stage III, unresectable NSCLC: A systematic review and meta-analysis.
    Liu, Lian
    Dai, Xin
    Li, Song
    Sheng, Lei
    Huang, Kai
    Chu, Jiahui
    Wang, Jian
    Li, Jisheng
    Liu, Yanguo
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
12345